Buserelin as primary therapy in advanced prostatic carcinoma

C. A. Presant, M. S. Soloway, S. S. Klioze, J. W. Kosola, A. L. Yakabow, R. G. Mendez, P. S. Kennedy, M. R. Wyres, V. L. Naessig, K. S. Ford

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.

Original languageEnglish
Pages (from-to)2416-2419
Number of pages4
JournalCancer
Volume56
Issue number10
DOIs
StatePublished - Dec 1 1985
Externally publishedYes

Fingerprint

Buserelin
Carcinoma
Therapeutics
Prostatic Neoplasms
Hot Flashes
Libido
Erectile Dysfunction
Gonadotropin-Releasing Hormone
Testosterone
Prostate
Adenocarcinoma
Quality of Life
Pain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Presant, C. A., Soloway, M. S., Klioze, S. S., Kosola, J. W., Yakabow, A. L., Mendez, R. G., ... Ford, K. S. (1985). Buserelin as primary therapy in advanced prostatic carcinoma. Cancer, 56(10), 2416-2419. https://doi.org/10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#

Buserelin as primary therapy in advanced prostatic carcinoma. / Presant, C. A.; Soloway, M. S.; Klioze, S. S.; Kosola, J. W.; Yakabow, A. L.; Mendez, R. G.; Kennedy, P. S.; Wyres, M. R.; Naessig, V. L.; Ford, K. S.

In: Cancer, Vol. 56, No. 10, 01.12.1985, p. 2416-2419.

Research output: Contribution to journalArticle

Presant, CA, Soloway, MS, Klioze, SS, Kosola, JW, Yakabow, AL, Mendez, RG, Kennedy, PS, Wyres, MR, Naessig, VL & Ford, KS 1985, 'Buserelin as primary therapy in advanced prostatic carcinoma', Cancer, vol. 56, no. 10, pp. 2416-2419. https://doi.org/10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#
Presant CA, Soloway MS, Klioze SS, Kosola JW, Yakabow AL, Mendez RG et al. Buserelin as primary therapy in advanced prostatic carcinoma. Cancer. 1985 Dec 1;56(10):2416-2419. https://doi.org/10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#
Presant, C. A. ; Soloway, M. S. ; Klioze, S. S. ; Kosola, J. W. ; Yakabow, A. L. ; Mendez, R. G. ; Kennedy, P. S. ; Wyres, M. R. ; Naessig, V. L. ; Ford, K. S. / Buserelin as primary therapy in advanced prostatic carcinoma. In: Cancer. 1985 ; Vol. 56, No. 10. pp. 2416-2419.
@article{deb53b965d7c4742b1647adde806b163,
title = "Buserelin as primary therapy in advanced prostatic carcinoma",
abstract = "The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54{\%}) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38{\%}), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38{\%}, patient-scored pain improved in 46{\%}, and quality of life improved in 57{\%}. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25{\%} increase in testosterone in 36{\%} of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.",
author = "Presant, {C. A.} and Soloway, {M. S.} and Klioze, {S. S.} and Kosola, {J. W.} and Yakabow, {A. L.} and Mendez, {R. G.} and Kennedy, {P. S.} and Wyres, {M. R.} and Naessig, {V. L.} and Ford, {K. S.}",
year = "1985",
month = "12",
day = "1",
doi = "10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#",
language = "English",
volume = "56",
pages = "2416--2419",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Buserelin as primary therapy in advanced prostatic carcinoma

AU - Presant, C. A.

AU - Soloway, M. S.

AU - Klioze, S. S.

AU - Kosola, J. W.

AU - Yakabow, A. L.

AU - Mendez, R. G.

AU - Kennedy, P. S.

AU - Wyres, M. R.

AU - Naessig, V. L.

AU - Ford, K. S.

PY - 1985/12/1

Y1 - 1985/12/1

N2 - The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.

AB - The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0022406964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022406964&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#

DO - 10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#

M3 - Article

C2 - 3930064

AN - SCOPUS:0022406964

VL - 56

SP - 2416

EP - 2419

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -